Healthcare- and pharma-economic models in support of the international consortium for personalised medicine
HEcoPerMed responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine and seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the requirements of personalised medicine for more compre-hensive cost-effectiveness estimates that incorporate patient and societal perspectives and enhance sustainable affordability of cutting-edge health innovations. HEcoPerMed will provide an overview of and guidance on high-quality methodological approaches for model-based economic evaluations. In three case studies, HEcoPerMedwill apply state-of-the art economic modelling to demonstrate practical and methodological issues in evaluating personalised medicine innovations. The project team will also study existing shortcomings in stimulating the adoption of personalised medicine and pro-pose financial agreements that accelerate its diffusion in European health systems.  HEcoPerMed will construct future scenarios, considering the trends and drivers as well as challenges and benefits of personalised medicine for the European social model of care and its financial viability. For a better financial integration of personalised medicine and new economic models, the project team will develop appropriate diffusion and communication strategies to be in direct contact with experts and a wide variety of stakeholders, taking their needs into account while offering new solutions for the players within the European health systems. These comprehensive measures will fill a gap identified by the ICPerMed to support their efforts in the promotion of personalised medicine in Europe and beyond. The project will support health care decision makers to manage their budgets while providing the best possible care for patients in the field of personalised medicine.